Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Jan-Feb;19(1):56.
doi: 10.4103/1319-3767.105930.

Rifaximin as treatment for hepatic encephalopathy: some considerations

Lorenzo Ridola, Angelo Zullo, Cesare Hassan
Comment

Rifaximin as treatment for hepatic encephalopathy: some considerations

Lorenzo Ridola et al. Saudi J Gastroenterol. 2013 Jan-Feb.
No abstract available

PubMed Disclaimer

Comment on

  • Hepatic encephalopathy.
    Bleibel W, Al-Osaimi AM. Bleibel W, et al. Saudi J Gastroenterol. 2012 Sep-Oct;18(5):301-9. doi: 10.4103/1319-3767.101123. Saudi J Gastroenterol. 2012. PMID: 23006457 Free PMC article. Review.

References

    1. Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012;16:133–46. - PubMed
    1. Bleibel W, Al-Osaimi AM. Hepatic encephalopathy. Saudi J Gastroenterol. 2012;18:301–9. - PMC - PubMed
    1. Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy. 2008;28:1019–32. - PubMed
    1. Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, et al. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther. 2012;3:62–7. - PMC - PubMed
    1. Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled study. J Hepatol. 2005;42:674–9. - PubMed

MeSH terms